Paper10698518
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP and 4 others. Oncogene, 2000. Cited by 84 papers, by iCite.
Cite this record
ConductScience Library. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Papers, record 10698518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10698518
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| DNA-Binding Proteins | Major topic |
| Estrogens | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Genes, erbB-2 | Major topic |
| Introns | Major topic |
| Neoplasm Proteins | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Receptors, Estrogen | Major topic |
| Transcription Factors | Major topic |
| Binding Sites | |
| Binding, Competitive | |
| DNA Footprinting | |
| Enhancer Elements, Genetic | |
| Female | |
| Histone Acetyltransferases | |
| Humans | |
| Ligands | |
| Mutagenesis, Site-Directed | |
| Nuclear Receptor Coactivator 1 | |
| Protein Binding | |
| Protein Conformation | |
| Proto-Oncogene Mas | |
| Transcription Factor AP-2 |
Source PubMed
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8290251 | Jun and Fos heterodimerize with ATFa, a member of the ATF/CREB family and modulate its transcriptional activity. | Oncogene | 1994 | https://conductscience.org/library/papers/8290251 | PubMed |
| 2 | 10629551 | Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. | J Pathol | 1999 | https://conductscience.org/library/papers/10629551 | PubMed |
| 3 | 8170474 | Characterization of ligand-dependent phosphorylation of the estrogen receptor. | Mol Endocrinol | 1994 | https://conductscience.org/library/papers/8170474 | PubMed |
| 4 | 1973827 | Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. | Oncogene | 1990 | https://conductscience.org/library/papers/1973827 | PubMed |
| 5 | 7477377 | Requirement for neuregulin receptor erbB2 in neural and cardiac development. | Nature | 1995 | https://conductscience.org/library/papers/7477377 | PubMed |
| 6 | 9541193 | Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. | Breast Cancer Res Treat | 1998 | https://conductscience.org/library/papers/9541193 | PubMed |
| 7 | 9252329 | AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. | Science | 1997 | https://conductscience.org/library/papers/9252329 | PubMed |
| 8 | 9427757 | Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. | EMBO J | 1998 | https://conductscience.org/library/papers/9427757 | PubMed |
| 9 | 7849263 | Negative transcriptional regulation by nuclear receptors. | Semin Cancer Biol | 1994 | https://conductscience.org/library/papers/7849263 | PubMed |
| 10 | 8670870 | TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. | EMBO J | 1996 | https://conductscience.org/library/papers/8670870 | PubMed |
| 11 | 9797688 | ERBB2 oncogene in human breast cancer and its clinical significance. | Eur J Cancer | 1998 | https://conductscience.org/library/papers/9797688 | PubMed |
| 12 | 8099725 | Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. | Oncogene | 1993 | https://conductscience.org/library/papers/8099725 | PubMed |
| 13 | 2885917 | erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. | Science | 1987 | https://conductscience.org/library/papers/2885917 | PubMed |
| 14 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 15 | 1680817 | Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. | Int J Cancer | 1991 | https://conductscience.org/library/papers/1680817 | PubMed |
| 16 | 7737129 | ATF-2 contains a phosphorylation-dependent transcriptional activation domain. | EMBO J | 1995 | https://conductscience.org/library/papers/7737129 | PubMed |
| 17 | 8895516 | A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. | Oncogene | 1996 | https://conductscience.org/library/papers/8895516 | PubMed |
| 18 | 9659924 | Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. | Mol Cell | 1998 | https://conductscience.org/library/papers/9659924 | PubMed |
| 19 | 9192902 | A signature motif in transcriptional co-activators mediates binding to nuclear receptors. | Nature | 1997 | https://conductscience.org/library/papers/9192902 | PubMed |
| 20 | 9642216 | Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9642216 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42315983 | Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer. | Histopathology | 2026 | https://conductscience.org/library/papers/42315983 | PubMed |
| 38643188 | Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis. | World J Surg Oncol | 2024 | https://conductscience.org/library/papers/38643188 | PubMed |
| 35654312 | Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women. | Cancer Epidemiol Biomarkers Prev | 2022 | https://conductscience.org/library/papers/35654312 | PubMed |
| 33920089 | Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33920089 | PubMed |
| 31801615 | Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. | Breast Cancer Res | 2019 | https://conductscience.org/library/papers/31801615 | PubMed |
| 29880033 | Membrane-bound estrogen receptor alpha initiated signaling is dynamin dependent in breast cancer cells. | Eur J Med Res | 2018 | https://conductscience.org/library/papers/29880033 | PubMed |
| 29880014 | Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. | Breast Cancer Res | 2018 | https://conductscience.org/library/papers/29880014 | PubMed |
| 24678732 | Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex. | Mol Endocrinol | 2014 | https://conductscience.org/library/papers/24678732 | PubMed |
| 24415978 | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. | Breast Care (Basel) | 2013 | https://conductscience.org/library/papers/24415978 | PubMed |
| 24367183 | Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. | Breast Cancer (Dove Med Press) | 2011 | https://conductscience.org/library/papers/24367183 | PubMed |
| 23991224 | Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. | PLoS One | 2013 | https://conductscience.org/library/papers/23991224 | PubMed |
| 23821662 | Estrogen represses gene expression through reconfiguring chromatin structures. | Nucleic Acids Res | 2013 | https://conductscience.org/library/papers/23821662 | PubMed |
| 22763464 | A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. | Breast Cancer Res Treat | 2012 | https://conductscience.org/library/papers/22763464 | PubMed |
| 22703232 | Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. | BMC Cancer | 2012 | https://conductscience.org/library/papers/22703232 | PubMed |
| 22190867 | Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles. | J Carcinog | 2011 | https://conductscience.org/library/papers/22190867 | PubMed |
| 22002538 | Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. | EMBO J | 2011 | https://conductscience.org/library/papers/22002538 | PubMed |
| 21396094 | Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. | Breast Cancer Res | 2011 | https://conductscience.org/library/papers/21396094 | PubMed |
| 21204711 | HER2: biology, detection, and clinical implications. | Arch Pathol Lab Med | 2011 | https://conductscience.org/library/papers/21204711 | PubMed |
| 20887199 | Mechanisms of endocrine resistance in breast cancer. | Annu Rev Med | 2011 | https://conductscience.org/library/papers/20887199 | PubMed |
| 19917725 | Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. | Mol Cell Biol | 2010 | https://conductscience.org/library/papers/19917725 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATF7 | 11016 | PubTator's text mining | https://conductscience.org/library/genes/11016 | NCBI Gene |
| CREB1 | 1385 | PubTator's text mining | https://conductscience.org/library/genes/1385 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| JUND | 3727 | PubTator's text mining | https://conductscience.org/library/genes/3727 | NCBI Gene |
| NCOA1 | 8648 | PubTator's text mining | https://conductscience.org/library/genes/8648 | NCBI Gene |
| SRC | 6714 | PubTator's text mining | https://conductscience.org/library/genes/6714 | NCBI Gene |
| TFAP2A | 7020 | PubTator's text mining | https://conductscience.org/library/genes/7020 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10698518
GET https://conductscience.org/api/papers/v1/10698518/references?page=2